Related Experiment Video
Updated: Oct 25, 2025
08:44
Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes
Published on: July 30, 2020
4.9K
Recent Advances in Liposomal-Based Anti-Inflammatory Therapy
Carla M A van Alem1, Josbert M Metselaar2, Cees van Kooten1
1Department of Internal Medicine, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Pharmaceutics
|August 10, 2021
Summary
Liposomes offer targeted delivery for anti-inflammatory drugs, enhancing efficacy and reducing side effects. Innovations in liposomal nanomedicines show promise, but clinical translation for inflammatory diseases faces challenges.
Area of Science:
- Nanomedicine
- Drug Delivery
- Inflammation Research
Background:
- Liposomes are ideal carriers for anti-inflammatory drugs due to passive targeting and localized release.
- Limited systemic exposure and adverse effects are key advantages.
- Few liposomal formulations have reached clinical application.
Purpose of the Study:
- To review recent innovations in liposomal treatment for inflammatory diseases.
- To highlight advancements in gene and RNA therapeutics delivery via liposomes.
- To discuss challenges in the clinical translation of liposomal nanomedicines.
Main Methods:
- Review of recent literature on liposomal formulations for inflammatory conditions.
- Focus on preclinical studies demonstrating efficacy and safety.
- Inclusion of select clinical studies for translational insights.
Main Results:
- Liposomal formulations demonstrate improved efficacy-safety ratios in preclinical models.
- Innovations include gene/RNA therapeutics and hybrid liposomal systems.
- Preclinical success does not always translate to clinical efficacy.
Conclusions:
- Liposomes show significant potential for treating inflammatory diseases like rheumatoid arthritis, psoriasis, and vascular inflammation.
- Advanced liposomal systems, including gene/RNA delivery, are emerging.
- Overcoming challenges in clinical translation is crucial for realizing the full potential of liposomal nanomedicines.
Related Concept Videos
01:27Bioavailability Enhancement: Drug Permeability Enhancement
35
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
35
01:29Inflammatory Bowel Disease IV: Pharmacological Management
245
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
245
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
251
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
251
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
264
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
264
01:29Drugs for Treatment of Ulcerative Colitis in IBD
279
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
279
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
290
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290